Navigation Links
Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
Date:4/25/2008

A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

In a late-breaking abstract presented at the 1st European Lung Cancer Conference jointly organized by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), Prof. Giorgio Scagliotti from the University of Torino, Italy presented data from the clinical trial stopped in February.

For some patients, the drug results in worse outcomes. "Based on a planned interim analysis the study showed a clear inferiority from adding sorafenib to carboplatin/paclitaxel in first-line non-small-cell lung cancer patients with squamous histology," Prof. Scagliotti said.

Sorafenib is an oral multikinase inhibitor with anti-angiogenic and antiproliferative activity. The drug, marketed as Nexavar by Bayer, is already approved for use in more than 40 countries for liver cancer and more than 70 countries for renal cell cancer.

The latest trial included 926 patients with unresectable stage IIIB/IV non-small-cell lung cancer who had received no prior systemic treatment. Patients were randomized to receive carboplatin plus paclitaxel, combined with either sorafenib 400 mg or placebo.

After a formal review of the ongoing study, the trial's data monitoring committee recommended termination. Preliminary results showed a median overall survival of 10.7 months in the sorafenib group vs 10.6 months in the placebo arm. Sorafenib-treated patients with squamous-cell non-small-cell lung cancer had a greater mortality rate than those with non-squamous histology.

"To date there is no evidence of any detrimental effect from sorafenib in ad
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Invention gives improved gene technology analysis
2. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
3. Genome analysis reveals new protein associated with breast cancer progression
4. Analysis Highlights Economic Contribution of Hospitals to Communities
5. SAIC Awarded DIA Intelligence Analysis Contract
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. Some Cancer Trials Overstate Findings, Analysis Claims
10. Review of group-based cancer trials reveals flaws in studies design and analysis
11. Stanford University School of Medicine to Address Improving Network Security and Management at EDUCAUSE Western Regional Conference 2008 Using Lancopes StealthWatch System for Network Behavior Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... made it clear that a mother,s eating habits prior ... profound impact on her offspring and their propensity for ... the mechanisms behind this phenomenon were unclear. According to ... The FASEB Journal F , scientists using ... mother,s diet and an offspring,s risk of future obesity. ...
(Date:9/2/2014)... believe that marijuana is not addictive, but a new ... able to obtain and consume cannabis legally for medical ... likely to perceive it as addictive or harmful," study ... Center for Addiction Medicine, said in a hospital news ... have significant consequences, and we know that among adolescents ...
(Date:9/2/2014)... Malvern, PA (PRWEB) September 02, 2014 ... healthcare communications and education, is proud to announce the ... and clinical resource center designed for healthcare professionals who ... website offers practitioners comprehensive access to:, , ... , Dedicated topic centers for diabetes, oncology, ...
(Date:9/2/2014)... Healthcare professionals will be able to access ... available at the point of care following an agreement ... Comprehensive Cancer Network® (NCCN®). Information from NCCN will ... the content available from the clinical reference tool ... of 25 of the world's leading cancer centers devoted ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
Breaking Medicine News(10 mins):Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2
... Results of VICTOR-E1 Phase II Study Presented at 15th ... Retroviruses and Opportunistic Infections (CROI), ... ) today reported that final results of a Phase ... potent,and sustained viral suppression through 48 weeks of therapy ...
... one can put on the brain cancer glioblastoma is that ... It is nearly always fatal, it tends to strike people ... options have changed little over decades. Its no wonder then ... this poorly understood type of cancer. , One approach ...
... New Deloitte Center for Health Solutions study outlines ... illnesses, coordinate care, WASHINGTON, Feb. 6 ... their patients, chronic diseases,and be compensated accordingly for ... study from the Deloitte Center for Health Solutions,( ...
... Revenues, Gross Margins and Net Income in Company History, ... DSCM ), a leading online provider of health, beauty, ... the fourth,quarter and fiscal year ended December 30, 2007. ... net income of $156,000, or $0.00,per share. The company ...
... - Q4 2007 ... - Q4 2007 book to bill ratio of 1.44, - ... ... PPD, Inc. (Nasdaq:,PPDI) today reported its financial and operating results for the fourth,quarter and full year ...
... ARLINGTON, Va., Feb. 6 The HealthCentral,Network, Inc. ... an accomplished dermatologist, cosmetic surgeon and author, is,joining ... expert. Sundaram is the author of Face Value: ... Finding It [Rodale], which was honored by,the National ...
Cached Medicine News:Health News:Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients 2Health News:Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients 3Health News:Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients 4Health News:Gene plays 'Jekyll and Hyde' in brain cancer 2Health News:Gene plays 'Jekyll and Hyde' in brain cancer 3Health News:The Medical Home: Building a Framework of Higher Quality, Reduced Cost and Patient-Centric Care 2Health News:The Medical Home: Building a Framework of Higher Quality, Reduced Cost and Patient-Centric Care 3Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 2Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 3Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 4Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 5Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 6Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 7Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 8Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 9Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 10Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 11Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 12Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 13Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 14Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 15Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 16Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 17Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com 2Health News:Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com 3
(Date:9/2/2014)...  PANTHERx Specialty Pharmacy announced today that it ... a Washington, DC -based health ... the health care industry. Logo - ... accreditation process demonstrates a commitment to quality services ... processes through benchmarking organizations against nationally recognized standards. ...
(Date:9/2/2014)... Actavis plc (NYSE: ACT ) ... (FDA) has accepted for filing Actavis, New Drug Application ... of diarrhea and abdominal pain in men and women ... for eluxadoline has been granted priority review status by ... "The NDA filing of eluxadoline marks an ...
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation ... previously announced agreement to purchase the Interventional business ... of Boston Scientific to offer physicians and healthcare ... treat challenging vascular conditions. The addition ... innovative technologies supports the Boston Scientific strategy to ...
Breaking Medicine Technology:PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: